ClinicalTrials.gg
CompletedNCT04447040Updated Mar 24, 2025Results posted

Acetaminophen/Naproxen Sodium Dose Ranging Study

A Phase 2 interventional study of Acetaminophen/naproxen sodium Dose A and Acetaminophen/naproxen sodium Dose B in Pain, sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Completed at 1 site in United States. Open to participants aged 17 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division (formerly part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
17 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies in Pain by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Pain · Johnson & Johnson.

Enrollment
32nd of 88
304 · median 183
Started
2020
the only one that year
Phase 2
14 of 104
none open now
Registered
100th of 104
by date

Among the 104 studies in Pain by Johnson & Johnson, this one is the 32nd largest by enrollment of the 88 interventional ones that give a count, is the only one that started in 2020, is one of 14 in phase 2, and was the 100th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 104 studies in Pain by Johnson & Johnson is open now. The open studies under Pain, anywhere →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 17 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 104 studies in Pain by Johnson & Johnson as a file.
02

Study summary

Study assessing the relative efficacy of five strengths of a fixed combination of acetaminophen and naproxen sodium is being investigated to help inform selection of dose(s) for further development and to evaluate the safety of a fixed combination of naproxen sodium and acetaminophen.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study to evaluate the analgesic efficacy and safety profile of the following doses of a fixed combination of Acetaminophen (APAP)/Naproxen sodium (NPX) administered as a single two-tablet dose:[Acetaminophen/Naproxen Sodium Dose A, Acetaminophen/Naproxen Sodium Dose B, Acetaminophen/Naproxen Sodium Dose C, Acetaminophen/Naproxen Sodium Dose D, Acetaminophen/Naproxen Sodium Dose E and Placebo] following surgical extraction of four third molars.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Analgesics
  • Dental Pain
  • Acetaminophen
  • Naproxen Sodium
  • Pain
  • Fixed-Dose
04

Who can participate

Ages eligible
17 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females 17-50 years old
  2. Weigh 100 pounds or greater and have a (BMI) of 17.5-35.4 (inclusive) at screening
  3. Surgical removal of three or four third molars, of which, two must be mandibular impactions
  4. Meets requirements for post-surgical pain level
  5. Females of and males agree to requirements of study
  6. Have a negative urine drug screen at screening, and on day of surgical procedure

Exclusion criteria

Exclusion Criteria:

  1. Pregnant female, breastfeeding, trying to become pregnant or male with pregnant partner or partner currently trying to become pregnant
  2. Have a known allergy or to naproxen or other NSAIDs, including aspirin, or to acetaminophen, oxycodone or other opioids;
  3. Not able to swallow whole large tablets or capsules
  4. History of any condition (s) in investigator's opinion, may jeopardize subject safety, well-being and integrity of study
  5. Use analgesics 5 or more times per week
  6. History of chronic tranquilizer use, heavy drinking, or substance abuse, as judged by the investigator site staff, in the last 5 years
  7. Use of any drugs within 2 weeks of screening
  8. History of endoscopically documented peptic ulcer disease or bleeding disorder in the last 2 years
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    Acetaminophen/naproxen sodium Dose A

    Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.

    Drug: Acetaminophen/naproxen sodium Dose A

  • Experimental
    Acetaminophen/naproxen sodium Dose B

    Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.

    Drug: Acetaminophen/naproxen sodium Dose B

  • Experimental
    Acetaminophen/naproxen sodium Dose C

    Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.

    Drug: Acetaminophen/naproxen sodium Dose C

  • Experimental
    Acetaminophen/naproxen sodium Dose D

    Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.

    Drug: Acetaminophen/naproxen sodium Dose D

  • Experimental
    Acetaminophen/naproxen sodium Dose E

    Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.

    Drug: Acetaminophen/naproxen sodium Dose E

  • Placebo comparator
    Placebo

    Placebo tablets administered as a single two-tablet dose.

    Drug: Placebo

Interventions

  • DrugAcetaminophen/naproxen sodium Dose A

    Acetaminophen/naproxen sodium Dose A administered as a single two-tablet dose.

  • DrugAcetaminophen/naproxen sodium Dose B

    Acetaminophen/naproxen sodium Dose B administered as a single two-tablet dose.

  • DrugAcetaminophen/naproxen sodium Dose C

    Acetaminophen/naproxen sodium Dose C administered as a single two-tablet dose.

  • DrugAcetaminophen/naproxen sodium Dose D

    Acetaminophen/naproxen sodium Dose D administered as a single two-tablet dose.

  • DrugAcetaminophen/naproxen sodium Dose E

    Acetaminophen/naproxen sodium Dose E administered as a single two-tablet dose.

  • DrugPlacebo

    Placebo tablets administered as a single two-tablet dose.

06

What researchers measure

Primary outcomes

  1. Time Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)

    Time weighted sum of the pain intensity difference (SPID) score is derived from pain intensity difference (PID) score. Pain intensity-numerical rating scale (PI-NRS) was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID score was the difference between baseline pain intensity and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the interval from 0 to 12 hours. The possible range of SPID for 0 to 12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief.

    Time frame: Baseline (0 hour) up to 12 hours post-dose on Day 1

Secondary outcomes

  1. Time Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)

    Time weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0 to10 (0 = no relief, 10 = complete relief). A higher score indicated greater pain relief. Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores were indicative of more pain relief.

    Time frame: Baseline (0 hour) up to 12 hours post-dose on Day 1

  2. Time Weighted Sum of Pain Intensity Difference Score From 6 Hours to 12 Hours (SPID 6-12)

    Time weighted sum of the pain intensity difference (SPID) score is derived from PID score. PI-NRS was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID was the difference between pain intensity at 6 hours and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the intervals from 6 to 12 hours (6 hours). The possible range of SPID for 6 to12 hours was from -60 to 60. A higher value of SPID indicated greater pain relief.

    Time frame: From 6 hours up to 12 hours post-dose on Day 1

  3. Time to First Use of Rescue Analgesic Medication

    Time to first use of rescue analgesic medication was measured as the elapsed time (in minutes) from when the investigational product was given until the time rescue analgesic was first given. Participants who did not use rescue medication during the 24 hour study period had their time to rescue set to 24 hours and were censored at 24 hours. Kaplan-Meier method was used for the analysis.

    Time frame: From 0 minute up to 1440 minutes post-dose (that is, up to 24 hours post-dose) on Day 1

  4. Proportion of Participants Who Required Rescue Analgesic Medication

    Proportion (cumulative data) of participants who used rescue analgesic medication through 24 hours post study drug administration on Day 1 which was assessed by using Kaplan-Meier estimates were reported.

    Time frame: From 0 hour up to 24 hours post-dose on Day 1

07

Results

Posted Apr 11, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose E
Started534953525146
Completed514749485043
Not completed224413
Withdrew: Lost to follow-up213313
Withdrew: Withdrawal by subject011100

Outcome measures

PrimaryTime Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)

Time weighted sum of the pain intensity difference (SPID) score is derived from pain intensity difference (PID) score. Pain intensity-numerical rating scale (PI-NRS) was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID score was the difference between baseline pain intensity and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the interval from 0 to 12 hours. The possible range of SPID for 0 to 12 hours was from -120 to 120. A higher value of SPID indicated greater pain relief.

Time frame:
Baseline (0 hour) up to 12 hours post-dose on Day 1
Reported as:
Least squares mean · Units on a scale
Time Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)
Units on a scalePlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose E
Time Weighted Sum of Pain Intensity Difference Score From Baseline (0 Hour) to 12 Hours (SPID 0-12)5.59 ± 3.74137.08 ± 3.89246.98 ± 3.74052.45 ± 3.77959.63 ± 3.81365.52 ± 4.027
Statistical analysis
  • Placebo vs Acetaminophen/Naproxen Sodium Dose A · ANOVA · p = <0.001 · Least square (ls) mean difference: 31.48 · 95% CI 20.90 to 42.07
  • Placebo vs Acetaminophen/Naproxen Sodium Dose B · ANOVA · p = <0.001 · Ls mean difference: 41.38 · 95% CI 31.02 to 51.75
  • Placebo vs Acetaminophen/Naproxen Sodium Dose C · ANOVA · p = <0.001 · Ls mean difference: 46.86 · 95% CI 36.44 to 57.27
  • Placebo vs Acetaminophen/Naproxen Sodium Dose D · ANOVA · p = <0.001 · Ls mean difference: 54.04 · 95% CI 43.57 to 64.51
  • Placebo vs Acetaminophen/Naproxen Sodium Dose E · ANOVA · p = <0.001 · Ls mean difference: 59.92 · 95% CI 49.16 to 70.68
SecondaryTime Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)

Time weighted total pain relief (TOTPAR) was measured using a Pain Relief Numerical Rating Scale (PR-NRS) ranging from 0 to10 (0 = no relief, 10 = complete relief). A higher score indicated greater pain relief. Total pain relief scores (TOTPARs) were calculated by multiplying the pain relief score at each post-dose time point by the duration (in hours) since the preceding time point and then summing these values. The minimum value was 0, and the maximum value was 120. Higher scores were indicative of more pain relief.

Time frame:
Baseline (0 hour) up to 12 hours post-dose on Day 1
Reported as:
Least squares mean · Units on a scale
Time Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)
Units on a scalePlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose E
Time Weighted Sum of Total Pain Relief Score From Baseline (0 Hour) to 12 Hours (TOTPAR 0-12)18.40 ± 4.55054.06 ± 4.73467.45 ± 4.54872.04 ± 4.59779.33 ± 4.63785.98 ± 4.898
Statistical analysis
  • Placebo vs Acetaminophen/Naproxen Sodium Dose A · ANOVA · p = <0.001 · Ls mean difference: 35.66 · 95% CI 22.79 to 48.54
  • Placebo vs Acetaminophen/Naproxen Sodium Dose B · ANOVA · p = <0.001 · Ls mean difference: 49.04 · 95% CI 36.44 to 61.65
  • Placebo vs Acetaminophen/Naproxen Sodium Dose C · ANOVA · p = <0.001 · Ls mean difference: 53.64 · 95% CI 40.97 to 66.31
  • Placebo vs Acetaminophen/Naproxen Sodium Dose D · ANOVA · p = <0.001 · Ls mean difference: 60.93 · 95% CI 48.19 to 73.67
  • Placebo vs Acetaminophen/Naproxen Sodium Dose E · ANOVA · p = <0.001 · Ls mean difference: 67.58 · 95% CI 54.49 to 80.67
SecondaryTime Weighted Sum of Pain Intensity Difference Score From 6 Hours to 12 Hours (SPID 6-12)

Time weighted sum of the pain intensity difference (SPID) score is derived from PID score. PI-NRS was used to assess pain intensity on scale ranged from 0 (no pain) to 10 (very severe pain), higher score indicated severe pain intensity. PID was the difference between pain intensity at 6 hours and pain intensity at assessment timepoint (12 hours). The SPID scores were derived by first multiplying each PID score by the time from the previous time point and adding these time weighted PID scores together over the intervals from 6 to 12 hours (6 hours). The possible range of SPID for 6 to12 hours was from -60 to 60. A higher value of SPID indicated greater pain relief.

Time frame:
From 6 hours up to 12 hours post-dose on Day 1
Reported as:
Least squares mean · Units on a scale
Time Weighted Sum of Pain Intensity Difference Score From 6 Hours to 12 Hours (SPID 6-12)
Units on a scalePlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose E
Time Weighted Sum of Pain Intensity Difference Score From 6 Hours to 12 Hours (SPID 6-12)2.58 ± 2.15415.12 ± 2.24120.31 ± 2.15324.47 ± 2.17627.59 ± 2.19531.89 ± 2.318
Statistical analysis
  • Placebo vs Acetaminophen/Naproxen Sodium Dose A · ANOVA · p = <0.001 · Ls mean difference: 12.53 · 95% CI 6.44 to 18.63
  • Placebo vs Acetaminophen/Naproxen Sodium Dose B · ANOVA · p = <0.001 · Ls mean difference: 17.73 · 95% CI 11.76 to 23.70
  • Placebo vs Acetaminophen/Naproxen Sodium Dose C · ANOVA · p = <0.001 · Ls mean difference: 21.88 · 95% CI 15.89 to 27.88
  • Placebo vs Acetaminophen/Naproxen Sodium Dose D · ANOVA · p = <0.001 · Ls mean difference: 25.01 · 95% CI 18.98 to 31.03
  • Placebo vs Acetaminophen/Naproxen Sodium Dose E · ANOVA · p = <0.001 · Ls mean difference: 29.30 · 95% CI 23.11 to 35.50
SecondaryTime to First Use of Rescue Analgesic Medication

Time to first use of rescue analgesic medication was measured as the elapsed time (in minutes) from when the investigational product was given until the time rescue analgesic was first given. Participants who did not use rescue medication during the 24 hour study period had their time to rescue set to 24 hours and were censored at 24 hours. Kaplan-Meier method was used for the analysis.

Time frame:
From 0 minute up to 1440 minutes post-dose (that is, up to 24 hours post-dose) on Day 1
Reported as:
Median · Minutes
Time to First Use of Rescue Analgesic Medication
MinutesPlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose E
Time to First Use of Rescue Analgesic Medication90.0 (38 to 1440)898.0 (33 to 1440)1195.0 (30 to 1440)NA (0 to 1440)NA (68 to 1440)NA (497 to 1440)
Statistical analysis
  • Placebo vs Acetaminophen/Naproxen Sodium Dose A · Wilcoxon test · p = <0.001
  • Placebo vs Acetaminophen/Naproxen Sodium Dose B · Wilcoxon test · p = <0.001
  • Placebo vs Acetaminophen/Naproxen Sodium Dose C · Wilcoxon test · p = <0.001
  • Placebo vs Acetaminophen/Naproxen Sodium Dose D · Wilcoxon test · p = <0.001
  • Placebo vs Acetaminophen/Naproxen Sodium Dose E · Wilcoxon test · p = <0.001
SecondaryProportion of Participants Who Required Rescue Analgesic Medication

Proportion (cumulative data) of participants who used rescue analgesic medication through 24 hours post study drug administration on Day 1 which was assessed by using Kaplan-Meier estimates were reported.

Time frame:
From 0 hour up to 24 hours post-dose on Day 1
Reported as:
Number · Proportion of participants
Proportion of Participants Who Required Rescue Analgesic Medication
Proportion of participantsPlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose E
Proportion of Participants Who Required Rescue Analgesic Medication0.792 (0.675 to 0.889)0.571 (0.439 to 0.711)0.519 (0.392 to 0.659)0.353 (0.239 to 0.500)0.353 (0.239 to 0.500)0.152 (0.076 to 0.293)
Statistical analysis
  • Placebo vs Acetaminophen/Naproxen Sodium Dose A · Wald method · p = 0.014
  • Placebo vs Acetaminophen/Naproxen Sodium Dose B · Wald method · p = 0.002
  • Placebo vs Acetaminophen/Naproxen Sodium Dose C · Wald method · p = <0.001
  • Placebo vs Acetaminophen/Naproxen Sodium Dose D · Wald method · p = <0.001
  • Placebo vs Acetaminophen/Naproxen Sodium Dose E · Wald method · p = <0.001

Adverse events

Collected over From baseline (Day 1; day of surgery) up to Day 10. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/53 (0%)0/53 (0%)12/53 (22.6%)
Acetaminophen/Naproxen Sodium Dose A0/49 (0%)0/49 (0%)7/49 (14.3%)
Acetaminophen/Naproxen Sodium Dose B0/53 (0%)0/53 (0%)6/53 (11.3%)
Acetaminophen/Naproxen Sodium Dose C0/52 (0%)0/52 (0%)5/52 (9.6%)
Acetaminophen/Naproxen Sodium Dose D0/51 (0%)0/51 (0%)3/51 (5.9%)
Acetaminophen/Naproxen Sodium Dose E0/46 (0%)0/46 (0%)3/46 (6.5%)
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose E
NauseaGastrointestinal disorders9/535/492/532/522/511/46
VomitingGastrointestinal disorders6/531/492/530/521/510/46
HeadacheNervous system disorders1/531/491/530/520/512/46
DizzinessNervous system disorders0/531/490/530/521/510/46
HaemorrhageVascular disorders0/531/490/531/520/510/46
BronchitisInfections and infestations0/530/490/530/521/510/46
RashSkin and subcutaneous tissue disorders0/530/490/530/521/510/46
HyperhidrosisSkin and subcutaneous tissue disorders0/530/490/531/520/510/46
PyrexiaGeneral disorders0/530/490/531/520/510/46
Alveolar osteitisInfections and infestations0/530/491/530/520/510/46

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose ETotal
Mean18.5 ± 1.7818.4 ± 1.8318.6 ± 2.0518.7 ± 1.9518.5 ± 1.8218.2 ± 1.5018.5 ± 1.83
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose ETotal
Female252726252724154
Male282227272422150
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose ETotal
Hispanic or Latino126522936
Not Hispanic or Latino404348504937267
Unknown or Not Reported1000001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAcetaminophen/Naproxen Sodium Dose AAcetaminophen/Naproxen Sodium Dose BAcetaminophen/Naproxen Sodium Dose CAcetaminophen/Naproxen Sodium Dose DAcetaminophen/Naproxen Sodium Dose ETotal
American Indian or Alaska Native0001001
Asian1112117
Native Hawaiian or Other Pacific Islander1011003
Black or African American1000001
White504851485045292
More than one race0000000
Unknown or Not Reported0000000
08

Study locations

1 site
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Data sharing details ↗ · yoda.yale.edu.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Apr 2021, 5 months.

Results were first posted in Apr 2024, 3 years after primary completion. A results delay was requested in Apr 2022.

Of 62 industry-sponsored phase 2 interventional studies under Pain, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 5 months is below that.

Counting every sponsor, half of 186 studies reached it within 21 months; a quarter within 7 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 25, 2020
StartActual
Nov 9, 2020
Primary completionActual
Apr 9, 2021
CompletionActual
May 3, 2021
Results delay requested
Apr 6, 2022
Results first posted
Apr 11, 2024
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04447040
Responsible party
Sponsor
First posted
Jun 25, 2020
Start date
Nov 9, 2020
Primary completion
Apr 9, 2021
Completion
May 3, 2021
Results posted
Apr 11, 2024
Last update
Mar 24, 2025

Study contacts

Todd Bertoch, MD
principal investigator · JBR Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion